NTRK3 and adenocarcinoma: Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel <i>R-Spondin2</i> RNA Fusion and <i>NTRK3</i> Mutation.